In 2019, the global hepatitis C drugs market was worth US$ 7,376.6 million, with a CAGR of 4.0 percent predicted during the forecast year (2019-2027).

 

Hepatitis C drugs Market

Hepatitis C is a liver infection that can cause significant damage to the liver.

Hepatitis C virus is to blame (HCV).

Hepatitis C is the world's most common blood-borne disease, and it's spread primarily through the use of intravenous drugs.

HCV can be transferred through unsanitary intercourse or contact with contaminated blood.

Hepatitis C is not vaccinated.

Furthermore, the hepatitis C medications market is predicted to rise throughout the forecast period due to the rising prevalence of the disease.




According to the World Health Organization (WHO), over 71 million persons worldwide were infected with chronic hepatitis C in 2017.

Furthermore, with prevalence rates of 2.3 percent and 1.5 percent, the WHO considers the Eastern Mediterranean and European regions to be the most afflicted.

The global hepatitis C medications market is predicted to develop due to increased regulatory approval of drugs.

Due to increased regulatory approval activities for hepatitis C medications, the market for hepatitis C drugs is likely to rise significantly over the forecast period.

Mavyret (glecaprevir and pibrentasvir) was licensed by the US Food and Drug Administration in 2017 for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1-6 who do not have cirrhosis (liver disease).

Mavyret is also approved for adult patients with HCV genotype 1 infection who have previously received treatment with either an NS5A inhibitor or an NS3/4A protease inhibitor.

Global Hepatitis C Drugs Market - Competitive Landscape

Key players operating in the global hepatitis C drugs market include Abbvie Inc., Gilead Sciences, Inc., BRISTOL-MYERS Squibb Company., F Hoffmann-la Roche Ltd, Merck & co., Inc., Johnson & Johnson, Natco Pharma Limited, and Kadmon Holdings, Inc.